Patent intelligence · US
US 12070510
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
Patent details — US 12070510
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 27, 2024
- Expiration
- Aug 22, 2044
- Applicant
- REGENXBIO INC.
- Claims
- 14
- CPC classes
- A61K, A61K45/06, A61K48/0075, A61K9/0085
Quick answer
US 12070510 (Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid) is held by REGENXBIO INC.. Status: granted. Granted Aug 27, 2024. Expires Aug 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENXBIO INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K45/06, A61K48/0075, A61K9/0085, A61P, A61P25/00
More from REGENXBIO INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 12070510?
US 12070510 (Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid) is held by REGENXBIO INC.. Status: granted. Granted Aug 27, 2024. Expires Aug 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12070510?
REGENXBIO INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 12070510 expire?
Our index shows an expiration date of Aug 22, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.